BACKGROUND
XenTech was founded in 2006 by researchers from the Institut Curie having over 15 years of experience in preclinical pharmacology in oncology. This spin-off company dedicated to biomarker discovery and preclinical evaluation of anticancer therapies is known worldwide for its expertise in the field of patient-derived tumor xenografts (PDX).
Located on the Genopole Campus, its experimental models are housed at the CERFE.
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
XenTech develops an innovative experimental platform based on one of the world’s largest collections of patient derived tumors xenografts (PDX). The collection is representative of the major types of cancer (breast, lung, colon, prostate) but also includes less common tumors (melanoma, ovarian cancer, renal cancer, pancreatic cancer, glioma, hepatoblastoma).
XenTech’s platform is of considerable value for translational research in oncology, notably for drug screening and the identification of biomarkers useful for precision oncology.
XenTech participates in the development of novel cancer therapies by offering its services, models and expertise in preclinical oncology to stakeholders in oncology research.
CUSTOMER REFERENCES / COLLABORATIONS / HIGHLIGHTS
- Partnership with the world’s biggest pharmaceutical companies involved in oncology.
- Partnerships with major Cancer Centers.
- Member of the ITCC-P4 consortium, a European IMI2 project to develop a platform for pediatric cancer models
COLLABORATIONS SOUGHT
- Collaborative partnership with the pharmaceutical industry on drug response biomarkers and new therapeutic targets discovery programs.
- Collaborative partnership with hospital structures to pursue development of the preclinical platform.
- Research fee-for-service contracts with pharmaceutical companies, biotechs and academic groups for evaluating antitumor efficacy of their drug candidates.
